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5 patients, 1 died 3 days after diagnosis. 4 patients had 
surgery, 3 developed DM and 1 is a long-term survivor. 
Median OS was 68 days. 
 
 
 
Conclusion: These rare sarcomas have variable clinical 
presentations. Surgery is the central component for 
successful treatment but complete resection is not always 
possible. RT may reduce LR (reduced from 77%, group B,to 
53%, group A) and chemotherapy is offered if high risk 
(inoperable, R2 margins, or DM). We still need to define the 
optimum management. 
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Purpose or Objective: To evaluate the impact of a dose 
escalation > 50 Gy in a large series of resected limbs soft 
tissue sarcomas (STS) 
 
Material and Methods: Data were retrospectively analyzed 
from 414 consecutive localized limbs STS patients who 
received irradiation and enlarged surgery at Gustave Roussy 
from 05/1993 to 05/2012. RT dose level were decided in 
multidisciplinary staff and depended upon the quality of 
surgery and margins size. 
 
Results: The median age was 52 years, the median tumor size 
was 89 mm, most patients had proximal locations (72%), and 
G-2-3 tumors (79%). Available histologic analyses after 
surgery retrieved 84% unifocal tumors and free-tumor margins 
>1 mm in 69% of cases. Radiotherapy (RT) was delivered prior 
(13%) or after (87%) surgery. Seven patients (2%) had pre- and 
a postoperative RT boost. Median delivered RT dose was 50 
Gy (36-70 Gy), and 40% received >50Gy. At a median follow-
up of 5.5 years, the 5-year local relapse rates (LRRs) were 
7%, 4%, and 13% in the general population, in patients 
receiving <50Gy and in those who had >50 Gy (p<0.001), 
respectively. Despite this may due to confounding factors, a 
dose >50 Gy (HR: 2.6; p=0.04) remained associated with 
higher LRRs in the multivariate analysis (MVA), as well as 
histological subtypes (HR: 3.7; p=0.002), and surgical 
margins<1mm (HR: 3.2; p=0.008). Grade, age, and tumour 
size were not associated with LRRs in the MVA. 
 
Conclusion: In this retrospective analysis of patients having 
enlarged and surgery and RT dose escalation did not allow 
offsetting local relapse in high-risk patients. This should be 
evaluated in a larger set of patients all having enlarged 
surgery. A Prospective study allowing dose refinement in this 
setting is required. 
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Purpose or Objective: Fluid collection of lymph or blood may 
accumulate at the site of excision after surgery for soft tissue 
sarcoma, with reported incidence rates from 10-36%. Though 
small fluid collections have a high probability of being 
completely covered within the postoperative radiotherapy 
(PORT) field, large fluid collections may require a more 
extensive expansion of CTVs. This study is an unprecedented 
analysis of fluid collection in relation to radiotherapy 
outcomes after wide excision of soft tissue sarcoma (STS). 
 
Material and Methods: Medical records of 151 patients with 
STS treated with wide excision followed by adjuvant PORT 
between 2004 and 2014 were retrospectively reviewed. Only 
non-recurrent and non-metastatic patients were included. 
After evaluation of CT and MR images taken at the time of 
PORT planning, fluid collection was detected in 46 patients 
(30.5%). Because fluid collection developed more commonly 
in lower extremity (p<0.001) and higher grade tumors 
(p=0.095), only these patients were included in further 
analyses (n=76). Fluid collection was present in 35 (46.1%) 
patients, of which 74.3% and 25.7% had, respectively, either 
complete or partial coverage in planning target volumes 
(PTVs) throughout the entire course of PORT. 
 
Results: After a median follow-up of 41 months, patients 
with and without fluid collection demonstrated local failure 
rates of 14.3% and 9.8%, and 5-year local control (LC) rates of 
83.1% and 86.8%, respectively. The presence of fluid 
collection had no statistical impact on the clinical outcomes 
of PORT. Partial coverage of fluid collection showed a low 5-
year LC rate of 77.8% compared with 85.5% and 86.8% for 
patients that had complete PTV coverage or absence of fluid 
collection, respectively, without statistical significance. Post-
PORT complications developed in 5 (6.6%) patients, of which 
4 had fluid collection. Wound complication developed in 3 
(8.6%) of 35 patients with fluid collection and in 1 (2.4%) of 
41 patients without fluid collection. 
 
Conclusion: Fluid collection demonstrated lower LC rates 
after wide excision and PORT for STS, but with a reasonable 
wound complication rate of 8.6% when compared with rates 
of previous studies ranging from 5-17%. Furthermore, partial 
coverage of fluid collections in PTVs had worse LC rates, thus 
recommending complete coverage. Future evaluation wth a 
larger number of cases will be needed for statistical support 
of our findings. 
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Purpose or Objective: If radiotherapy (RT) combined with 
extended resection is part of the standard treatment of high 
risk extremity soft tissue sarcomas (ESTS), the evidence 
regarding the optimal target volume of RT ensuring local 
control (LC) is not very robust. But it is well known that 
toxicity is directly related to the RT volume and the 
delivered dose. The development of image-guided 
radiotherapy and implementation of better target volume 
conformation could reduce toxicity without compromising 
outcome. Here we evaluate the definition of RT volume 
according to clinical, surgical and histological factors. 
 
Material and Methods: Between the 1st January 2008 and the 
31th Decembre 2009, 173 patients from eleven centers with 
ESTS were retrospectively evaluated, all patients having had 
resection with pre- or post-operative RT. Primary endpoint 
was to evaluate the target volume and RT dose and their 
impact on LC and patterns of local relapse (LR). Secondary 
endpoints were: impact of surgery’s quality on LC, patterns 
of relapse and RT volume. Impact of RT dose on LC and 
patterns of LR. Impact of histological type on LC and on 
recurrent pattern. Impact of RT volume on toxicity (CTC 
V.04). 
 
Results: Median age was 60 years [19-91]. 32% of patients 
had upper limb and 68% lower limb STS. Median tumor size 
was 75mm [17-270]. RT was preoperative in 12% and 
postoperative in 88% of cases. Quality of surgery was R0 in 
62%; R0 after second surgery in 11% and R1 in 27% patients. 
Intraoperative tumor fragmentation rate was 6% in expert 
centers and 16% in non-expert centers. Most frequent 
histologic types were liposarcoma (31%) and 
myxofibrosarcoma (13%). Median dose was 54 Gy [36-70]. 
Median PTV1 and PTV2 volumes were 864cc [25-5122] and 
443cc [20-1613] respectively. LR rate was 11.20% (n=20); 45% 
within PTV1, 28% in the PTV2, 18% at the edge of the RT 
volume and 9% outside. 21.4% of patients had a metastatic 
failure. Regarding toxicity, we observed 19.6% and 15.2% of 
G1 and G2 fibrosis, 19.6% and 12.5% of G1 and G2 edema, 
12.6% and 4.5% G1 and G2 pain, 3.4% and 6.9% of G1 and G2 
joint stiffness, 5.2% and 6.9% G1 and G2 neuropathy. Bone 
fracture occurred in 3.2% of cases. After univariate analysis, 
intraoperative tumor fragmentation was related to a higher 
risk of LR (22% vs 8% p=0,004) and distant metastasis (50% vs 
17% p= 0,0029). Including scar drainage in the RT field was 
correlated to a lower LR rate (9% vs 29% p= 0,015). Upper 
limb location was correlated with higher risk of neuropathy 
(p=0,049) and lower limb location was correlated with edema 
(p=0,024). Dose > 60 Gy did not impact on LC but was 
correlated with pain (p=0,021). No significant correlation 
with fibrosis could be identified. 
 
Conclusion: As in other studies, the quality of surgery is the 
most important prognostic factor predicting outcome. Most of 
LR were within the PTV field translating a correct target 
volume definition. Toxicity was acceptable. A prospective 
evaluation is warranted. 
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Purpose or Objective: Radiotherapy remains the cornerstone 
of treatment for patients with DIPG. Nevertheless, median 
overall survival of patients initially responding to 
radiotherapy is poor. The role of chemotherapy as second-
line treatment remains elusive. Purpose of this study is to 
analyze the benefit and toxicity of re-irradiation at the time 
of disease progression. 
 
Material and Methods: At the time of disease progression 27 
children, aged 2 to 16, underwent re-irradiation (10 fractions 
of 1.8, 2.0 or 3.0 Gy) alone (N=21) or combined with systemic 
therapy (N=6). At first diagnosis, all patients had symptoms 
for ≤3 months, ≥2 signs of the neurological triad (cranial 
nerve deficit, ataxia, long tract signs), characteristic 
features of DIPG on magnetic resonance imaging or biopsy 
proven high-grade glioma. An interval of ≥3 months after 
first-line radiotherapy was required before re-irradiation. A 
group of 39 patients fulfilling the same diagnostic criteria 
receiving radiotherapy at primary diagnosis, followed by best 
supportive care (N=10) or systemic therapy (N=19), were 
eligible for a matched-cohort analysis. 
 
Results: Median overall survival for patients undergoing re-
irradiation was 15.9 months. For a similar median time to 
first progression (8.1 vs. 7.7 months; P=.22), a significant 
benefit in median overall survival (15.9 [95% CI 13.0-20.0] vs. 
10.3 [95% CI 9.4-12.5] months; P=<.01) was observed in favor 
of patients undergoing re-irradiation compared to no re-
irradiation. The median overall survival benefit of re-
irradiation versus no re-irradiation was most pronounced in 
patients with a longer interval between end-of-radiotherapy 
and first progression (3-6 months: 11.1 vs. 8.7; P=<.01; 6-12 
months: 19.4 vs. 13.8; P=.02). On multivariable analysis 
corrected for age and systemic therapy, re-irradiation 
remained prognostic for overall survival (HR 0.43 [0.13-81]; 
P=<.01). Clinical improvement after re-irradiation was 
observed in 15/20 (75%) patients. No grade 4 or 5 acute or 
late toxicity was diagnosed. 
 
Conclusion: The majority of patients with DIPG, responding 
to first-line radiotherapy, do benefit of re-irradiation. A 
prospective data collection, supported by the SIOP-E-
HGG/DIPG working group, will start for patients fulfilling the 
criteria of re-irradiation. 
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